Prostate Cancer Awareness Month: The Urologist and Oncologist Perspectives

4 Views
Published
In honor of Prostate Cancer Awareness Month, Stephen Freedland, MD, and Ulka Vaishampayan, MD, share expert urology and oncology perspectives on prostate cancer, featuring the following topics:

• Emerging research in MRI, PSMA, and PET scans for early detection
• Novel biomarkers under investigation and efforts to incorporate them in screening
• Questions surrounding treatment for biochemical relapse
• Advances in systemic therapy
• The importance of creating individualized treatment plans based on biomarkers, genomic sequencing, disease aggressiveness, and other factors
• Recent approvals of radiopharmaceutical therapies, hormonal therapies, and other therapeutic advances
• The higher incidence of prostate cancer among African Americans and the need for earlier screening
• Ways to identify and combat barriers surrounding access to care and clinical trial participation
• And more!

“There is something to be said for us going to the patients rather than patients continuously approaching us for clinical trials. If we change that design, we’ll potentially engage more people. Hopefully this Prostate Cancer Awareness Month, all of us will think about expanding our approach towards quality of care to all patients within the community.” – Ulka Vaishampayan, MD

About Dr. Freedland and Dr. Vaishampayan

Stephen Freedland, MD, is Director of the Center for Integrated Research in Cancer and Lifestyle and Associate Director for Education and Training at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in Los Angeles. He also is the Warschaw Robertson Law Families Chair in Prostate Cancer and a Professor in the Department of Urology at Cedars-Sinai. He also holds a Staff Physician appointment at the Durham VA Medical Center in Durham, North Carolina. Dr. Freedland has published over 700 articles and served on numerous AUA and ASCO guideline panels for prostate cancer. His research interests include the role of diet, lifestyle, and obesity in cancer, cancer health disparities, and cancer risk stratification.

Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center. She is also the Chair of the SWOG Advanced Renal Committee, a member of the NCI Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development.
Category
Urology
Be the first to comment